After medication teaching on Atenolol, which of the following statements by the client with diabetes mellitus demonstrates an understanding of atenolol? "It may

A. Epinephrine: Epinephrine is primarily used in cardiac arrest or severe anaphylaxis to stimulate the heart and increase perfusion. While it increases heart rate and blood pressure, it is not the first-line treatment for symptomatic bradycardia in a patient who is still perfusing and has a palpable pulse.

B. Atropine: The patient is presenting with symptomatic bradycardia (heart rate 62 bpm, hypotension, pallor, diaphoresis, and shortness of breath). Atropine is the first-line therapy because it blocks vagal stimulation, increases sinoatrial node firing, and enhances AV conduction. It rapidly improves heart rate and perfusion in symptomatic bradycardia.

C. Adenosine: Adenosine is used to terminate supraventricular tachycardia by transiently blocking AV nodal conduction. It is contraindicated in bradycardia and would worsen the patient’s hypotension and symptoms, making it inappropriate.

D. Amiodarone: Amiodarone is used for ventricular arrhythmias or refractory tachyarrhythmias. It does not address bradycardia and could potentially exacerbate the slow heart rate, so it is not indicated for this patient’s presentation.

A. Mask an early sign of hypoglycemia: Atenolol is a beta-adrenergic blocker that can blunt sympathetic nervous system responses, such as tachycardia and tremors, which are early warning signs of hypoglycemia. Diabetic patients taking atenolol may not recognize low blood sugar until more severe symptoms, like dizziness or confusion, occur, so monitoring glucose closely is essential.

B. Cause hyperglycemia: Atenolol does not directly raise blood glucose levels. While nonselective beta-blockers may slightly affect glucose metabolism, atenolol, a cardioselective beta-1 blocker, is unlikely to cause clinically significant hyperglycemia in most patients.

C. Increase the action of insulin: Atenolol does not enhance insulin’s effect. Its primary actions are on heart rate and cardiac output, not insulin sensitivity or glucose uptake, so this reflects a misunderstanding of the drug’s pharmacology.

D. Decrease the action of insulin: Atenolol does not directly inhibit insulin activity. Although beta-blockers may interfere with certain metabolic responses, atenolol does not significantly alter insulin effectiveness, making this an incorrect understanding.